Literature DB >> 22822108

Accuracy, calibration and clinical performance of the new EuroSCORE II risk stratification system.

Umberto Di Dedda1, Gabriele Pelissero, Beatrice Agnelli, Carlo De Vincentiis, Serenella Castelvecchio, Marco Ranucci.   

Abstract

OBJECTIVES: The European System for Cardiac Operative Risk Evaluation (EuroSCORE) has been used for many years since its introduction in 1999. Recently, a new EuroSCORE (EuroSCORE II) has been developed to update the previous version. The EuroSCORE II includes some different predictors and/or introduces a new classification of the already existing predictors. This study presents a validation series for the EuroSCORE II compared with the previous additive and the logistic EuroSCORE and with the Age, Creatinine and Ejection Fraction (ACEF) score.
METHODS: A total of 1090 consecutive adult patients operated on at our institution from September 2010 to October 2011 were admitted to this retrospective study. All the patients received a risk stratification based on the EuroSCORE II and the other scores considered. Accuracy, calibration and clinical performance of the various risk models were assessed.
RESULTS: The accuracy of the EuroSCORE II was good (c-statistic 0.81) but not significantly higher than the other scores (range 0.78-0.8). Calibration at the Hosmer-Lemeshow statistic was good for all the scores; the difference between observed (3.75%) and predicted mortality in the overall population was not significant for the EuroSCORE II (3.1%) and the ACEF score (3.4%), whereas the additive EuroSCORE (5.8%) and the logistic EuroSCORE (7.3%) significantly overestimated the risk. In patients at low, mild moderate and high mortality risk, the EuroSCORE II provided a risk prediction not significantly different from the observed mortality rate, whereas in very high-risk patients (observed mortality rate 11%), it significantly underestimated (6.5%) the mortality risk. The accuracy of the EuroSCORE II was acceptable in isolated coronary surgery, and good or excellent in the other operations.
CONCLUSIONS: The EuroSCORE II represents a useful update of the previous EuroSCORE version, with a much better clinical performance and the same good level of accuracy. It is possible that for the risk stratification of very high-risk patients, other factors (rare but associated with a mortality rate >50%) should be included in the future models.

Entities:  

Mesh:

Year:  2012        PMID: 22822108     DOI: 10.1093/ejcts/ezs196

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  15 in total

1.  Performance of EuroSCORE II compared to EuroSCORE I in predicting operative and mid-term mortality of patients from a single center after combined coronary artery bypass grafting and aortic valve replacement.

Authors:  Kyriakos Spiliopoulos; Vasilis Bagiatis; Oliver Deutsch; Bernhard M Kemkes; Nikolaos Antonopoulos; Dimos Karangelis; Ayman Haschemi; Brigitte Gansera
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-08-29

2.  Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization.

Authors:  Nadia Bouabdallaoui; Susanna R Stevens; Torsten Doenst; Mark C Petrie; Nawwar Al-Attar; Imtiaz S Ali; Andrew P Ambrosy; Anna K Barton; Raymond Cartier; Alexander Cherniavsky; Pierre Demondion; Patrice Desvigne-Nickens; Robert R Favaloro; Sinisa Gradinac; Petra Heinisch; Anil Jain; Marek Jasinski; Jerome Jouan; Renato A K Kalil; Lorenzo Menicanti; Robert E Michler; Vivek Rao; Peter K Smith; Marian Zembala; Eric J Velazquez; Hussein R Al-Khalidi; Jean L Rouleau
Journal:  Circ Heart Fail       Date:  2018-11       Impact factor: 8.790

3.  Risk and Outcome of Aortic Valve Surgery in the Transcatheter Valve Era: The Gender Aspect.

Authors:  Georg Heinze; Torsten Christ; Christopher O Leonards; Pascal M Dohmen; Wolfgang Konertz
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-05-25       Impact factor: 1.520

4.  Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes.

Authors:  Carey Kimmelstiel; David C Zisa; Johny S Kuttab; Sophie Wells; James E Udelson; Benjamin S Wessler; Hassan Rastegar; Navin K Kapur; Andrew R Weintraub; Barry J Maron; Martin S Maron; Ethan J Rowin
Journal:  Circ Cardiovasc Interv       Date:  2019-07-12       Impact factor: 6.546

5.  In search of the ideal risk-scoring system for very high-risk cardiac surgical patients: a two-stage approach.

Authors:  Marco Ranucci; Umberto Di Dedda; Serenella Castelvecchio; Maria Teresa La Rovere; Lorenzo Menicanti
Journal:  J Cardiothorac Surg       Date:  2016-01-19       Impact factor: 1.637

6.  Mortality prediction in Indian cardiac surgery patients: Validation of European System for Cardiac Operative Risk Evaluation II.

Authors:  Prachi Kar; Kanithi Geeta; Ramachandran Gopinath; Padmaja Durga
Journal:  Indian J Anaesth       Date:  2017-02

7.  Is the EuroSCORE II reliable to estimate operative mortality among octogenarians?

Authors:  Sophie Provenchère; Arnaud Chevalier; Walid Ghodbane; Claire Bouleti; Philippe Montravers; Dan Longrois; Bernard Iung
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

8.  Major themes for 2012 in cardiovascular anesthesia and intensive care.

Authors:  H Riha; P Patel; L Al-Ghofaily; E Valentine; A Sophocles; J G T Augoustides
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2013

9.  Development of a predictive model for major adverse cardiac events in a coronary artery bypass and valve population.

Authors:  Christine R Herman; Karen J Buth; Jean-François Légaré; Adrian R Levy; Roger Baskett
Journal:  J Cardiothorac Surg       Date:  2013-07-30       Impact factor: 1.637

Review 10.  Validation of the EuroSCORE II in a Greek Cardiac Surgical Population: A Prospective Study.

Authors:  G Stavridis; D Panaretos; O Kadda; D B Panagiotakos
Journal:  Open Cardiovasc Med J       Date:  2017-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.